Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic.
Packer
M
M
D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D004656:Enalapril; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D011392:Proline / Q000031:analogs & derivatives*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012306:Risk; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D004151:Dipeptides; D014665:Vasodilator Agents; D004656:Enalapril; D011392:Proline; D002216:Captopril